What is Wedbush’s Estimate for TYRA FY2029 Earnings?

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Equities research analysts at Wedbush issued their FY2029 earnings estimates for shares of Tyra Biosciences in a report released on Friday, March 28th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($0.91) per share for the year. Wedbush has a “Outperform” rating and a $30.00 price objective on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.57) per share.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05.

Other equities analysts also recently issued reports about the stock. UBS Group assumed coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $30.83.

Tyra Biosciences Stock Down 6.2 %

NASDAQ:TYRA opened at $8.72 on Monday. Tyra Biosciences has a twelve month low of $8.66 and a twelve month high of $29.60. The firm has a market capitalization of $441.26 million, a price-to-earnings ratio of -5.42 and a beta of 1.09. The stock’s 50 day moving average price is $12.18 and its two-hundred day moving average price is $16.13.

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors have recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new stake in Tyra Biosciences in the 4th quarter valued at $31,000. US Bancorp DE acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth $50,000. BNP Paribas Financial Markets bought a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $60,000. Aquatic Capital Management LLC acquired a new position in shares of Tyra Biosciences in the fourth quarter valued at about $64,000. Finally, Wells Fargo & Company MN increased its position in Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after acquiring an additional 3,236 shares during the period. Institutional investors own 84.14% of the company’s stock.

Insider Buying and Selling at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 3,993 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total value of $65,325.48. Following the transaction, the director now owns 3,707,420 shares in the company, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 21,998 shares of company stock valued at $344,818 in the last quarter. 15.40% of the stock is currently owned by insiders.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.